![]() Median age (50 vs 48 years) and race (91% White) were similar for neoadjuvant and adjuvant-only patients. ![]() The majority, 76% (n = 35), had neoadjuvant therapy with adjuvant treatment and 24% (n = 11) had only adjuvant treatment. Neratinib status and start/stop dates were abstracted from the physician narrative, and duration of neratinib treatment was the difference between the start and stop dates, inclusive of dose holds.įorty-six patients with EBC who received neratinib as extended adjuvant treatment enrolled in the registry in December 2018. Treatment information came from EHR via machine learning with physician review. We evaluated personal/tumor characteristics for those who did and did not receive neoadjuvant therapy and treatment received. ![]() Electronic health records (EHRs) for EBC treatment were collected 7 years pre- to 1 year post enrollment. Patients were recruited mainly through social media, patient advocacy group and the Puma patient texting program. Neat-HER was a United States virtual registry pilot of patients with early HER2-positive breast cancer (EBC) receiving neratinib as extended adjuvant therapy in clinical practice.Įligibility included age 18 years and older and no clinical trial participation. There is interest in neratinib’s treatment patterns after pertuzumab and T-DM1 use. Neratinib’s (Nerlynx) pivotal study was performed before pertuzumab (Perjeta) and trastuzumab emtansine (Kadcyla T-DM1) adjuvant approvals. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |